Orphalan Employee Directory
Pharmaceutical ManufacturingÎle-de-France, France51-200 Employees
Orphalan, a mid-sized pharmaceutical company based in Paris, Île-de-France, specializes in the development and commercialization of treatments for rare diseases. Its portfolio centers on orphan drugs intended to address serious, low-prevalence conditions and to improve patient access to therapy. The company markets Cuvrior, a trientine tetrahydrochloride treatment for Wilson disease, which was launched in the United States in 2023. In December 2025, Orphalan announced the acquisition of Orphelia Pharma, a French company focused on rare and serious pediatric diseases, particularly in neurology and oncology. Earlier in 2025, it formed partnerships with MAP International and the Wilson Disease Association to provide Cuvrior to patients with Wilson disease in developing countries.
1-888-653-2347 
support@leadiq.com 
